Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 3
CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition cal…
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Estimated
~$10 – $7,500
Novo Nordisk A/SNCT07207811
Phase 2
A Phase IIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo in Adult Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen an…
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Estimated
~$10 – $7,500
AstraZenecaNCT07608354
Myocardial & Hepatic Shear Wave Velocity Measurements in Patients With Non-Reduced-Ejection Fraction Heart Failure and Control Subjects - US Benchmarking Clinical Study
The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failu…
HFpEF - Heart Failure With Preserved Ejection FractionHFmrEFATTR-CM (Transthyretin Amyloid Cardiomyopathy)+2 more
Estimated
~$10 – $1,125
eMyosound SASNCT07215715
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patie…
Alpha-ThalassemiaBeta-ThalassemiaAmyloidosis+14 more
Estimated
~$10 – $1,125
xCuresNCT06539169